Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) – Investment analysts at Jefferies Financial Group issued their Q1 2019 earnings per share (EPS) estimates for Amphastar Pharmaceuticals in a research note issued on Tuesday, March 12th. Jefferies Financial Group analyst D. Steinberg forecasts that the company will post earnings per share of $0.06 for the quarter. Jefferies Financial Group also issued estimates for Amphastar Pharmaceuticals’ Q2 2019 earnings at $0.08 EPS, Q3 2019 earnings at $0.13 EPS and Q4 2019 earnings at $0.18 EPS.
Several other equities analysts have also recently issued reports on AMPH. Zacks Investment Research cut shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, February 20th. Piper Jaffray Companies lowered shares of Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $24.00 to $23.00 in a research note on Wednesday. Needham & Company LLC lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating and set a $22.20 price objective on the stock. in a research note on Wednesday. Finally, BidaskClub raised shares of Amphastar Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, March 3rd. Three investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $23.73.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Tuesday, March 12th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.11 by $0.02. Amphastar Pharmaceuticals had a negative net margin of 1.96% and a positive return on equity of 3.25%. The firm had revenue of $89.69 million during the quarter, compared to analysts’ expectations of $75.46 million.
In related news, CFO William J. Peters sold 1,500 shares of the stock in a transaction on Monday, March 4th. The shares were sold at an average price of $25.36, for a total transaction of $38,040.00. Following the transaction, the chief financial officer now directly owns 77,050 shares of the company’s stock, valued at $1,953,988. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Jason B. Shandell sold 15,497 shares of the stock in a transaction on Wednesday, January 23rd. The stock was sold at an average price of $22.39, for a total transaction of $346,977.83. Following the transaction, the insider now directly owns 168,518 shares in the company, valued at $3,773,118.02. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 87,222 shares of company stock worth $2,037,797. Insiders own 31.50% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC boosted its stake in Amphastar Pharmaceuticals by 9.5% during the fourth quarter. Geode Capital Management LLC now owns 425,301 shares of the company’s stock worth $8,462,000 after acquiring an additional 36,784 shares in the last quarter. Nordea Investment Management AB boosted its stake in Amphastar Pharmaceuticals by 4.4% during the fourth quarter. Nordea Investment Management AB now owns 249,728 shares of the company’s stock worth $4,970,000 after acquiring an additional 10,569 shares in the last quarter. Public Employees Retirement System of Ohio bought a new position in Amphastar Pharmaceuticals during the fourth quarter worth $235,000. Millennium Management LLC boosted its stake in Amphastar Pharmaceuticals by 66.3% during the fourth quarter. Millennium Management LLC now owns 140,507 shares of the company’s stock worth $2,796,000 after acquiring an additional 56,001 shares in the last quarter. Finally, Municipal Employees Retirement System of Michigan bought a new position in Amphastar Pharmaceuticals during the fourth quarter worth $201,000. 48.22% of the stock is currently owned by institutional investors and hedge funds.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.
Read More: Hedge Funds – Risk or Reward?
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.